Clinical Trials Logo

Clinical Trial Summary

This is a non-randomized, phase II, open label study of Apatinib Mesylate in patients with with locally advanced or metastatic differentiated thyroid carcinoma (DTC). The purpose of this study is to evaluate the efficacy and safety of apatinib in patients with locally advanced or metastatic differentiated thyroid carcinoma.


Clinical Trial Description

At present, multiple anti-angiogenesis drugs for thyroid cancer of clinical research are ongoing worldwide, and most of which achieved fairly good therapeutic effect. To date, sorafenib has been approved for the treatment of radioactive iodine refractory DTC. Apatinib is a highly selective VEGFR2 inhibitor that reduces the angiogenesis of tumor efficiently, and had been proven to be effective in many solid tumors. In this study, the investigators aim to further explore the efficacy and safety of apatinib in locally advanced or metastatic differentiated thyroid carcinoma. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03167385
Study type Interventional
Source Tianjin Medical University Cancer Institute and Hospital
Contact Ming Gao, MD
Phone 862223340123
Email gaoming@tjmuch.com
Status Recruiting
Phase Phase 2
Start date March 22, 2017
Completion date December 31, 2020

See also
  Status Clinical Trial Phase
Completed NCT00251316 - Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer Phase 2
Recruiting NCT06359847 - Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer Phase 2
Recruiting NCT01704586 - I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer N/A
Completed NCT03776123 - Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients
Not yet recruiting NCT04916262 - Correlation Between TCM Syndrome Factors and TSH Changes of Thyroid Hormone Withdrawal Before Iodine Therapy in Postoperative Patients With Thyroid Cancer
Active, not recruiting NCT04970134 - Spanish Study for Molecular Characterization of Thyroid Carcinoma
Completed NCT00439127 - OnT4-Thyroglobulin Assay Before rhTSH-Aided Radioiodine Ablation N/A
Recruiting NCT03845647 - Significance of Contralateral Central Lymph Node Dissection in Unilateral cN0 Differentiated Thyroid Carcinoma. N/A